Please login to the form below

Not currently logged in
Email:
Password:

Servier

This page shows the latest Servier news and features for those working in and with pharma, biotech and healthcare.

Orphan drugs dominate FDA's record-breaking year

Orphan drugs dominate FDA's record-breaking year

Servier’s Asparlas (calaspargase pegol), a long-acting drug for acute lymphoblastic leukaemia that also extends the dosing interval for patients.

Latest news

More from news
Approximately 16 fully matching, plus 81 partially matching documents found.

Latest Intelligence

  • 2019: CRISPR and therapeutic gene editing comes of age 2019: CRISPR and therapeutic gene editing comes of age

    At this year’s American Society of Haematology (ASH) meeting, Allogene and partner Servier presented phase 1 data for their UCART19 candidate in ALL which revealed impressive response rates.

  • Pharma deals continue to slide Pharma deals continue to slide

    The Xoma licensing deal is interesting because it required Novartis to settle the $14m debt owed to Xoma’s previous licensee Servier.

  • Deal Watch March 2017 Deal Watch March 2017

    name. (Abexinostat was formerly in development by Pharmacyclics (now owned by AbbVie) and Servier.) Both ACAT-1 (for which Xynomic paid $1.2m upfront with another $59m in potential milestones) and

  • Deal Watch January 2017 Deal Watch January 2017

    What goes around, comes around The appetite for immuno-oncology (IO) has survived well into 2017 with Servier closing the biggest IO headline deal in January with Pieris for $1.7bn ... 3, 050. Pieris Pharmaceuti-cals. Servier. Exclusive licence outside

  • Deal Watch July 2016 Deal Watch July 2016

    At the other end of the development spectrum Servier paid the same amount upfront for the rights to Sorrento's immuno-oncology product: STI-A1110, an anti-PD-1 mAb, presently ... Licence. 1, 115. Sorrento Therapeutics/ Servier. STI-A1110 - anti-PD1

More from intelligence
Approximately 0 fully matching, plus 29 partially matching documents found.

Latest appointments

More from appointments
Approximately 1 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Four Health

Beautiful things happen when you put the right ingredients together. It’s the reason that we mix behaviour change experts with...

Latest intelligence

Cell and gene therapy
Tackling the manufacturing cost and complexity challenges...
2019: CRISPR and therapeutic gene editing comes of age
Can gene-editing deliver safe and effective therapeutics for patients with intractable diseases?...
The 10-year Web Challenge
Understanding your users’ needs is more critical online today than ever. A site should mould itself around these insights, deliver those needs quickly, efficiently and with plenty of white space....

Infographics